Pan-immune-inflammation value as an independent prognostic marker in patients with brain metastases
PIV is an independent prognostic factor for OS in BM patients. Incorporating this marker into the Graded Prognostic Assessment modestly improves risk stratification and supports an accessible nomogram for individualized survival prediction. External prospective validation, including longitudinal assessment of the pan-immune-inflammation value and integration with molecular and imaging markers, is needed before routine clinical implementation.
Authors
- M. Liu
- Yingtong Liu
- Yuping Xie (ORCID: https://orcid.org/0000-0002-2064-6277)
- Jiacheng Li (ORCID: https://orcid.org/0000-0002-0224-9139)
- Jiazhen Liu
- Zheran Liu
Institutions
- University of Electronic Science and Technology of China (CN)
- Sichuan University (CN)
- West China Medical Center of Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Fourth People's Hospital of Sichuan Province (CN)
- Sichuan Cancer Hospital (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.3389/fonc.2025.1718288
- Citations
- 2
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 48.39
Funders
- Nuclear Power Institute of China
- National Natural Science Foundation of China
- Sichuan University
- National Science and Technology Major Project
- Health Commission of Sichuan Province
- Sichuan Province Science and Technology Support Program
- West China Hospital, Sichuan University